HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Top Cited Papers
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 127 (1), 72-84
- https://doi.org/10.1016/j.ophtha.2019.04.017
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma
This publication has 33 references indexed in Scilit:
- An update on the pharmacotherapy of neovascular age-related macular degenerationExpert Opinion on Pharmacotherapy, 2013
- ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE StudyOphthalmology, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Stability engineering of scFvs for the development of bispecific and multivalent antibodies"Protein Engineering, Design and Selection", 2010
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Single-Chain Antigen-Binding ProteinsScience, 1988